Compare · NVS vs PHVS
NVS vs PHVS
Side-by-side comparison of Novartis AG (NVS) and Pharvaris N.V. (PHVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and PHVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $305.27B, about 117.7x PHVS ($2.59B).
- PHVS has hit the wire 7 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 14 for PHVS).
- Company
- Novartis AG
- Pharvaris N.V.
- Price
- -
- -
- Market cap
- $305.27B
- $2.59B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 7
- Recent ratings
- 25
- 14
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
Latest PHVS
- Chief Executive Officer Modig Berndt sold $79,686 worth of shares (2,292 units at $34.77) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 130,625 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Pharvaris N.V.
- SEC Form 144 filed by Pharvaris N.V.
- President Lu Peng covered exercise/tax liability with 226 shares, decreasing direct ownership by 0.35% to 65,179 units (SEC Form 4) to satisfy tax liability
- SEC Form 6-K filed by Pharvaris N.V.
- Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
- Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
- Amendment: SEC Form SCHEDULE 13G/A filed by Pharvaris N.V.
- Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
- Chief Executive Officer Modig Berndt sold $80,154 worth of shares (2,292 units at $34.97) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 132,917 units (SEC Form 4)